Literature DB >> 28108853

Brain metastasis of carcinoma ex pleomorphic adenoma of the parotid gland: case report and review of the literature.

Ruth Lau1, Alejandro Fernández-Coello2, Noemí Vidal-Sarró3, Dennis Céspedes2, Angels Camins4, Miren Taberna5,6,7, Andreu Gabarrós2.   

Abstract

We present an extremely infrequent case of brain metastasis of a parotid tumor. To our knowledge, this is the second case reported of a brain metastasis of a malignant parotid tumor, carcinoma ex pleomorphic adenoma. Pleomorphic adenoma represents 60% of tumors of the parotid gland, and although it is a benign tumor, it can transform into carcinoma ex pleomorphic adenoma in 5% of cases, one of the most aggressive neoplasms of the salivary glands. We want to note the need for an accurate diagnostic. Thanks to aggressive surgical management, our patient survived more than 1½ years.

Entities:  

Keywords:  Brain metastasis; Carcinoma ex pleomorphic adenoma; Parotid tumor

Mesh:

Year:  2017        PMID: 28108853     DOI: 10.1007/s00701-017-3080-9

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  3 in total

1.  Carcinoma Ex Pleomorphic Adenoma of the Parotid Gland: A Rare Case.

Authors:  Zaryab Umar; Usman Ilyas; Mohsen S Alshamam; Allison Foster; Rubal Bhangal; Nazaakat Ahmed; Zarwa Idrees
Journal:  Cureus       Date:  2022-05-26

2.  Oxidative Stress Markers Patients with Parotid Gland Tumors: A Pilot Study.

Authors:  Pawel Sowa; Maciej Misiolek; Bartlomiej Pasinski; Grzegorz Bartosz; Miroslaw Soszynski; Monika Adamczyk-Sowa; Izabela Sadowska-Bartosz
Journal:  Biomed Res Int       Date:  2018-01-30       Impact factor: 3.411

3.  Trastuzumab Emtansine for the Treatment of HER-2 Positive Carcinoma Ex-pleomorphic Adenoma Metastatic to the Brain: A Case Report.

Authors:  Ihab Hassanieh; Lara Hilal; Karine A Al Feghali; Ibrahim Khalifeh; Bassem Youssef
Journal:  Front Oncol       Date:  2018-07-24       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.